|  |
| --- |
| **Supplementary Table 2. Results of subgroup analysis** |
| **Outcome** | **Subgroup** | **Trials, *n*** | **HR or RR (95% CI), *p*** | ***I*2, *p*** | **Test for subgroup differences** |
| OS | Sample size ≤500 | 4 | HR=0.89, 0.74-1.07, 0.21 | 35%, 0.20 | 0%, 0.71 |
| Sample size >500 | 3 | HR=0.84, 0.63-1.10, 0.21 | 82%, 0.004 |
| DCR | Sample size ≤500 | 5 | RR=1.33, 1.02-1.73, 0.03 | 71%, 0.007 | 0%, 0.79 |
| Sample size >500 | 3 | RR=1.40, 1.10-1.77, 0.006 | 80%, 0.006 |
| TTP | Sample size ≤500 | 5 | HR=0.66, 0.48-0.92, 0.01 | 80%, 0.0004 | 0%, 0.81 |
| Sample size >500 | 3 | HR=0.62, 0.41-0.94, 0.02 | 92%, 0.00001 |
| PFS | Sample size ≤500 | 3 | HR=0.64, 0.42-0.99, 0.05 | 87%, 0.0003 | 0%, 0.53 |
| Sample size >500 | 2 | HR=0.54, 0.40-0.74, 0.0001 | 78%, 0.03 |
| AEs of any grade | Sample size ≤500 | 4 | RR=1.05, 0.90-1.24, 0.52 | 87%, 0.0001 | 0%, 0.88 |
| Sample size >500 | 2 | RR=1.07, 1.04-1.10, 0.00001 | 0%, 0.43 |
| Decreased appetite | Sample size ≤500 | 5 | RR=1.57, 1.00-2.44, 0.05 | 70%, 0.009 | 0%, 0.93 |
| Sample size >500 | 2 | RR=1.62, 0.91-2.88, 0.10 | 81%, 0.02 |
| Diarrhea | Sample size ≤500 | 5 | RR=1.57, 1.11-2.23, 0.01 | 42%, 0.14 | 0%, 0.47 |
| Sample size >500 | 3 | RR=1.92, 1.26-2.93, 0.002 | 73%, 0.02 |
| Fatigue | Sample size ≤500 | 5 | RR=1.63, 1.05-2.54, 0.03 | 70%, 0.009 | 9%, 0.29 |
| Sample size >500 | 3 | RR=1.27, 1.07-1.50, 0.006 | 0%, 0.41 |
| Ascites | Sample size ≤500 | 4 | RR=1.46, 0.79-2.72, 0.23 | 76%, 0.005 | 0%, 0.64 |
| Sample size >500 | 3 | RR=1.22, 0.79-1.89, 0.37 | 74%, 0.02 |
| Vomiting | Sample size ≤500 | 3 | RR=2.14, 1.27-3.61, 0.004 | 0%, 0.40 | 46.6%, 0.17 |
| Sample size >500 | 3 | RR=1.25, 0.72-2.20, 0.43 | 73%, 0.02 |
| Constipation | Sample size ≤500 | 3 | RR=1.29, 0.57-2.94, 0.54 | 70%, 0.04 | 0%, 0.63 |
| Sample size >500 | 3 | RR=1.03, 0.64-1.64, 0.91 | 67%, 0.05 |
|  AE, adverse event; CI, confidence interval; DCR, disease control rate; HR, hazard ratio; RR, relative risk; OS, overall survival; PFS, progression-free survival; TTP, time to progression. |